These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19168790)

  • 1. ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.
    Stankiewicz MJ; Crispino JD
    Blood; 2009 Apr; 113(14):3337-47. PubMed ID: 19168790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERG is a megakaryocytic oncogene.
    Salek-Ardakani S; Smooha G; de Boer J; Sebire NJ; Morrow M; Rainis L; Lee S; Williams O; Izraeli S; Brady HJ
    Cancer Res; 2009 Jun; 69(11):4665-73. PubMed ID: 19487285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.
    Ge Y; LaFiura KM; Dombkowski AA; Chen Q; Payton SG; Buck SA; Salagrama S; Diakiw AE; Matherly LH; Taub JW
    Leukemia; 2008 Mar; 22(3):521-9. PubMed ID: 18094719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.
    Birger Y; Goldberg L; Chlon TM; Goldenson B; Muler I; Schiby G; Jacob-Hirsch J; Rechavi G; Crispino JD; Izraeli S
    Blood; 2013 Aug; 122(6):988-98. PubMed ID: 23719302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis.
    Klusmann JH; Godinho FJ; Heitmann K; Maroz A; Koch ML; Reinhardt D; Orkin SH; Li Z
    Genes Dev; 2010 Aug; 24(15):1659-72. PubMed ID: 20679399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divergent functions of hematopoietic transcription factors in lineage priming and differentiation during erythro-megakaryopoiesis.
    Pimkin M; Kossenkov AV; Mishra T; Morrissey CS; Wu W; Keller CA; Blobel GA; Lee D; Beer MA; Hardison RC; Weiss MJ
    Genome Res; 2014 Dec; 24(12):1932-44. PubMed ID: 25319996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
    Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
    PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proto-oncogene ERG in megakaryoblastic leukemias.
    Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
    Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.
    Stankiewicz MJ; Crispino JD
    Leukemia; 2013 Jun; 27(6):1339-47. PubMed ID: 23380710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
    Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
    JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
    Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
    Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ets-dependent regulation of target gene expression during megakaryopoiesis.
    Jackers P; Szalai G; Moussa O; Watson DK
    J Biol Chem; 2004 Dec; 279(50):52183-90. PubMed ID: 15466856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
    Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early lineage priming by trisomy of Erg leads to myeloproliferation in a Down syndrome model.
    Ng AP; Hu Y; Metcalf D; Hyland CD; Ierino H; Phipson B; Wu D; Baldwin TM; Kauppi M; Kiu H; Di Rago L; Hilton DJ; Smyth GK; Alexander WS
    PLoS Genet; 2015 May; 11(5):e1005211. PubMed ID: 25973911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intricate regulatory circuit between FLI1 and GATA1/GATA2/LDB1/ERG dictates erythroid vs. megakaryocytic differentiation.
    Wang C; Hu M; Yu K; Liu W; Hu A; Kuang Y; Huang L; Gajendran B; Zacksenhaus E; Xiao X; Ben-David Y
    Mol Med Rep; 2024 Jun; 29(6):. PubMed ID: 38695236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling.
    Malinge S; Thiollier C; Chlon TM; Doré LC; Diebold L; Bluteau O; Mabialah V; Vainchenker W; Dessen P; Winandy S; Mercher T; Crispino JD
    Blood; 2013 Mar; 121(13):2440-51. PubMed ID: 23335373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development.
    Takasaki K; Chou ST
    Adv Exp Med Biol; 2024; 1459():261-287. PubMed ID: 39017848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factor GATA-1 and Down syndrome leukemogenesis.
    Muntean AG; Ge Y; Taub JW; Crispino JD
    Leuk Lymphoma; 2006 Jun; 47(6):986-97. PubMed ID: 16840187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.